Dr. Layal El Raichani

Dr. Layal El Raichani
Dr. Layal El Raichani
Pharmacist, Centre intégré de santé et services sociaux de l’Outaouais and Adjunct Professor at the School of Pharmaceutical Sciences

PharmD, University of Montreal, 2015
MSc Advanced Pharmacotherapy, University of Montreal, 2016
Fellowship in Oncology, Centre Hospitalier de l’Université de Montréal (CHUM), 2018



Biography

Early in her PharmD studies at Université de Montréal, Dr Layal El Raichani's interest quickly turned to hospital practice. She thus completed her master's degree in advanced pharmacotherapy in 2016, followed by a fellowship in hemato-oncology at the Centre Hospitalier de l'Université de Montréal (CHUM) in 2018. After practicing for approximately two years at Charles LeMoyne Hospital on the south shore of Montreal, Layal El Raichani is currently practicing in oncology at the Hôpital de Gatineau since 2020.

Providing quality patient care and acting as a drug specialist are two of her priorities. Teaching, mentoring students and residents, and training the next generation of pharmacists are particularly important to her.

Expertise

  • Hematology
  • Oncology
  • Pharmacotherapy
  • Pharmaceutical practice

Research Projects

During her training, Layal El Raichani has been exposed to clinical research. Her projects have led to publications in the field of renal transplantation as well as in oncology. She has also participated in several international congresses where she presented the results of her research.

Sensitized to clinical research and its importance, she is currently involved in the supervision of master's students in their research project.

  • Letarte N, El Raichani L, Guevremont C, et al. Real-life use of nivolumab and pembrolizumab in four adult university teaching hospitals in Québec, Canada. Journal of Clinical Oncology. 2019;37(15_suppl). doi:10.1200/jco.2019.37.15_suppl.e14125  
  • Elkrief A, El Raichani L, Richard C, et al. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. OncoImmunology. 2019;8(4). doi:10.1080/2162402x.2019.1568812
  • El Raichani L, Du Q, Mathieu A, et al. Development and validation of part (pharmacotherapy assessment in renal transplant patients) criteria to assess drug‐related problems in an outpatient renal transplant population: A cross‐sectional study. Pharmacology Research & Perspectives. 2019;7(1). doi:10.1002/prp2.453
  • R Alameddine, P Wong, A Gagné, M-A Hamel, J Malo, A El Krief, L El Raichani, W Belkaid, M Messaoudene, M Orain, M Florescu, K Belanger, N Blais, M Tehfe, R Jamal, N Letarte, P Joubert, B Routy Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer and melanoma: a real-life data from a multicentric cohort in Canada. Poster presented at: International Society of Geriatric Oncology; November 2018.

Award and Nominations

  • Dean's Honour Roll of the PharmD program (2015), Convocation of the Faculty of Pharmacy of University of Montreal